SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin rises as arm receives USFDA approval for Generic Plan B Tablets

25 Jan 2013 Evaluate

Lupin is currently trading at Rs. 590.05, up by 0.90 points or 0.15% from its previous closing of Rs. 589.15 on the BSE.

The scrip opened at Rs. 592.00 and has touched a high and low of Rs. 594.10 and Rs. 590.05 respectively. So far 2,205 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 631.90 and a 52 week low of Rs. 412.15.

The current market cap of the company is Rs. 26,392.00 crore.

The promoters holding in the company stood at 46.85% while Institutions and Non-Institutions held 43.40% and 9.75% respectively.

Pharma major, Lupin’s subsidiary - Lupin Pharmaceuticals Inc (collectively Lupin) has received final approval for its Levonorgestrel Tablets USP, 0.75 mg (Rx/OTC) from the United States Food and Drugs Administration (US FDA) to market a generic version of Teva Branded Pharmaceutical Products R&D, Inc.’s Plan B Tablets, 0.75 mg.

Lupin’s Levonorgestrel Tablets Levonorgestrel 0.75mg tablets is a progestin?only emergency contraceptive, indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure.

Plan B Tablets had annual US sales of approximately $81.1 million (IMS MAT Sept 2012 sales).

Lupin Share Price

2324.25 -2.25 (-0.10%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×